Table 5.
Average dose of the bladder for 15 new prostate cancer volumetric modulated arc therapy plans in each dose constraint and planning model
| Organ | Dose constraints | Model | Mean (%)±SD | P |
|---|---|---|---|---|
| Bladder | V80 <15% | MP | 6.7±2.5 | Reference |
| RP20 | 6.4±2.5 | 0.007 | ||
| RP60 | 6.1±2.4 | <0.001 | ||
| RP120 | 6.2±2.5 | <0.001 | ||
| RP120A | 6.4±2.6 | 0.004 | ||
| V75 <25% | MP | 8.9±3.1 | Reference | |
| RP20 | 8.8±3.0 | 0.420 | ||
| RP60 | 8.3±2.9 | <0.001 | ||
| RP120 | 8.3±3.1 | <0.001 | ||
| RP120A | 8.6±3.2 | 0.02 | ||
| V70 <30% | MP | 10.7±3.6 | Reference | |
| RP20 | 10.6±3.4 | 0.820 | ||
| RP60 | 10.0±3.4 | 0.002 | ||
| RP120 | 9.90±3.5 | <0.001 | ||
| RP120A | 10.1±3.6 | 0.070 | ||
| V60 <40% | MP | 14.2±4.7 | Reference | |
| RP20 | 14.1±4.5 | 0.850 | ||
| RP60 | 13.3±4.4 | 0.003 | ||
| RP120 | 13.4±4.8 | 0.001 | ||
| RP120A | 13.6±4.8 | 0.140 | ||
| V40 <50% | MP | 25.9±8.1 | Reference | |
| RP20 | 26.0±7.8 | 0.900 | ||
| RP60 | 24.4±8.0 | 0.050 | ||
| RP120 | 23.9±7.8 | 0.008 | ||
| RP120A | 25.3±8.2 | 0.410 |
SD: Standard deviation, MP: Manually optimized plans, RP: RapidPlan